Last reviewed · How we verify
EU-sourced Xgeva — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
EU-sourced Xgeva (EU-sourced Xgeva) — mAbxience Research S.L.. Binds to and inhibits RANKL, preventing osteoclast formation and bone resorption.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| EU-sourced Xgeva TARGET | EU-sourced Xgeva | mAbxience Research S.L. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- EU-sourced Xgeva CI watch — RSS
- EU-sourced Xgeva CI watch — Atom
- EU-sourced Xgeva CI watch — JSON
- EU-sourced Xgeva alone — RSS
Cite this brief
Drug Landscape (2026). EU-sourced Xgeva — Competitive Intelligence Brief. https://druglandscape.com/ci/eu-sourced-xgeva. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing